Lab Research lands new preclinical R&D contracts

By Gareth Macdonald

- Last updated on GMT

Related tags: Lab research, Pharmacology

New multi-million dollar R&D contracts with top three pharma and biotech players go someway to “alleviating” the negative impact of downturn, according to Lab Research CEO Luc Mainville.

The firm, which also signed an R&D deal with a European agrochemicals major, will undertake preclinical research on behalf the as yet unidentified drug industry majors at its testing facility in Laval in Quebec, Canada.

Over the last three years Lab Research has spent C$65m (€41.8) expanding the lab as well as two other testing facilities in Denmark and Hungary adding capacity which, Mainville said, had played a part in winning the new R&D contracts.

He told Outsourcing-pharma that: “It is clear that adding scale and broadening our services to include bioanalytical, drug metabolism, reproductive toxicology and more inhalation have been key factors.

But I think that it is a combination of our capabilities and high quality and flexibility as a mid-size lab that has contributed to each of these agreements​.”

Mainville also highlighted Lab Research’s expertise and track record in safety pharmacology, infusion and primate modelling as being the key technical capabilities that had landed the new contracts.

He concluded that: “Clearly our ability to expand our client audience to include larger and sophisticated recurrent spenders has alleviated somewhat the negative impact of the recession​.”

In a press release accompanying the announcement Lab Research said that the contracts are likely to lead to more deals later this year, adding that discussions are already ongoing for work to be conducted over the next two years.

The non-clinical contract research organisation (CRO) predicted that the latest deals and subsequent agreements will contribute between five and 10 per cent of its total revenue for the current year.

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us

Products

View more

Webinars